Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID‐19-Reference-Cited by-同舟云学术

Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID‐19

Published:2021-08-31 Issue:6 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Passante Maria¹,Napolitano Maddalena²^ORCID,Dastoli Stefano¹,Bennardo Luigi¹^ORCID,Fabbrocini Gabriella³^ORCID,Nisticò Steven Paul¹,Patruno Cataldo¹

Affiliation:

1. Department of Health Sciences University Magna Graecia of Catanzaro Catanzaro Italy

2. Department of Health Sciences V. Tiberio University of Molise Campobasso Italy

3. Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15111

Reference9 articles.

1. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety

2. ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting inteleukins, immunoglobulins and complement factors);Winthrop KL;Clin Microbiol Infect,2018

3. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab

4. Use of biologicals in allergic and type‐2 inflammatory diseases during the current COVID‐19 pandemic: position paper of Ärzteverband Deutscher Allergologen (AeDA)a, deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co‐operation with the German, Austrian, and Swiss ARIA groups G, and the European academy of allergy and clinical immunology (EAACI)H;Klimek L;Allergol Select,2020

5. The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation;Life;2024-03-13

2. COVID-19 and Its Impact on Common Diseases in the Allergy Clinics;The Journal of Allergy and Clinical Immunology: In Practice;2023-11

3. COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports;Dermatology Reports;2023-08-24

4. Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?;Dermatology Practical & Conceptual;2023-07-31

5. The Frequency and Severity of COVID-19 in Patients Receiving Biological Agents and Risk Factors: Experience of an Allergy Clinic;Asthma Allergy Immunology;2023-04-07